Market Overview

UPDATE: Ascendiant Capital Markets Reiterates Buy Rating, Lowers PT on StemCells

Related STEM
Morning Market Losers
Medical Action Industries Leads Healthcare Sector; Aerie Pharmaceutical Meets Clinical Endpoints

In a report published Monday, Ascendiant Capital Markets reiterated its Buy rating on StemCells (NASDAQ: STEM), but slightly lowered its price target from $2.60 to $2.25.

Ascendiant Capital noted, “The Company ended the quarter with cash of $22 MM. Thus far in Q4, they have raised an additional $5.6 MM in cash from the exercise of warrants and sale of additional shares via their ATM facility. We are decreasing our Q4 2012 GAAP EPS, and 2013 GAAP EPS estimate, to reflect the higher number of shares outstanding. For Q4, our EPS estimate is lowered by $0.03 to ($0.15), and for 2013, our EPS estimate is decreased by $0.11 to ($0.58).”

StemCells closed on Friday at $1.76.

Latest Ratings for STEM

DateFirmActionFromTo
Nov 2012Ascendiant Capital MarketsMaintainsBuy
Oct 2012Ascendiant Capital MarketsInitiates Coverage onBuy

View More Analyst Ratings for STEM
View the Latest Analyst Ratings

Posted-In: Ascendiant Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (STEM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters